12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      AuNP Pyrazolo[3,4-d]pyrimidine Nanosystem in Combination with Radiotherapy against Glioblastoma.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gold-nanoparticle (AuNP)-conjugated drugs represent a promising and innovative antitumor therapeutic approach. In our study, we describe the design, the synthesis, the preparation, and the characterization of AuNPs conjugated with the pyrazolo[3,4-d]pyrimidine derivative SI306, a c-Src inhibitor. AuNPs-SI306 showed a good loading efficacy (65%), optimal stability in polar media and in human plasma, and a suitable morphological profile: a ζ-potential of -43.9 mV, a nanoparticle diameter of 48.6 nm, and a 0.441 PDI value. The antitumoral activity of AuNPs-SI306 was evaluated in vitro in the glioblastoma model, by the low-density growth assay, and also in combination with radiotherapy (RT). Results demonstrated that AuNPs had a basal radiosensitization ability and that AuNPs-SI306, when used in combination with RT, were more effective in inhibiting tumor cell growth with respect to AuNPs and free SI306.

          Related collections

          Author and article information

          Journal
          ACS Med Chem Lett
          ACS medicinal chemistry letters
          American Chemical Society (ACS)
          1948-5875
          1948-5875
          May 14 2020
          : 11
          : 5
          Affiliations
          [1 ] Dipartimento Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via A. Moro 2, 53100 Siena, Italy.
          [2 ] Dipartimento di Farmacia, Università di Pisa, Via Bonanno Pisano 12, 56126 Pisa, Italy.
          [3 ] Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università dell'Aquila, Via Vetoio, 67100 Aquila, Coppito, Italy.
          [4 ] Faculty of Sciences, Laboratory of Physical Chemistry of Condensed Materials, University of Tunis El Manar, 2092 Tunis, Tunisia.
          [5 ] Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Viale Benedetto XV 3, 16132 Genova, Italy.
          [6 ] Lead Discovery Siena S.r.l., Via Vittorio Alfieri 31, Castelnuovo Berardenga, 53019 Siena, Italy.
          [7 ] Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Biolife Science Building, Suite 333, 1900 North 12th Street, Philadelphia, Pennsylvania 19122, United States.
          Article
          10.1021/acsmedchemlett.9b00538
          7236040
          32435368
          49c96758-ccdd-41e0-b783-a450336956c8
          History

          Comments

          Comment on this article

          scite_
          0
          0
          0
          0
          Smart Citations
          0
          0
          0
          0
          Citing PublicationsSupportingMentioningContrasting
          View Citations

          See how this article has been cited at scite.ai

          scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

          Similar content156

          Cited by6